Alkermes Stock Earnings Estimates Boosted by HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS estimate to a loss of $0.56 per share from a loss of $0.71, while maintaining a Neutral rating and $50 price target. It projects Alkermes will return to annual profitability in 2027, with EPS of $0.24.
• Alkermes reported quarterly EPS of $0.09, beating the consensus estimate of a $0.08 loss; revenue of $480.13 million also exceeded expectations and rose 21.8% year over year.
• Analyst sentiment is broadly positive: the stock has a Moderate Buy consensus rating and an average price target of $55.06, while institutional investors own 95.21% of shares.

Alkermes plc (NASDAQ:ALKS - Free Report) - HC Wainwright increased their FY2026 earnings per share estimates for shares of Alkermes in a report issued on Wednesday, November 4th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.56) per share for the year, up from their previous forecast of ($0.71). HC Wainwright has a "Neutral" rating and a $50.00 price target on the stock. The consensus estimate for Alkermes' current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Alkermes' Q4 2026 earnings at ($0.28) EPS, Q1 2027 earnings at ($0.03) EPS, Q2 2027 earnings at $0.08 EPS, Q3 2027 earnings at $0.16 EPS, Q4 2027 earnings at $0.03 EPS, FY2027 earnings at $0.24 EPS, FY2028 earnings at $0.08 EPS, FY2029 earnings at $0.86 EPS and FY2030 earnings at $1.66 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.17. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The firm had revenue of $480.13 million during the quarter, compared to the consensus estimate of $463.48 million. During the same period in the prior year, the business earned $0.49 EPS. The firm's revenue was up 21.8% compared to the same quarter last year.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company upped their price target on Alkermes from $65.00 to $68.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 4th. Stifel Nicolaus reiterated a "buy" rating and issued a $63.00 price objective (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. Robert W. Baird set a $61.00 price objective on shares of Alkermes in a research note on Wednesday, November 4th. JPMorgan Chase & Co. upped their price objective on shares of Alkermes from $60.00 to $61.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 29th. Finally, Truist Financial started coverage on shares of Alkermes in a research report on Friday, October 16th. They set a "buy" rating and a $55.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $55.06.

Alkermes Trading Up 0.6%

Shares of ALKS stock opened at $46.47 on Wednesday. The company has a market capitalization of $7.81 billion, a P/E ratio of -2,322.34 and a beta of 0.32. The company has a current ratio of 2.42, a quick ratio of 2.02 and a debt-to-equity ratio of 0.79. The business's 50 day moving average is $43.67 and its two-hundred day moving average is $40.92. Alkermes has a twelve month low of $27.00 and a twelve month high of $55.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in Alkermes by 2.5% in the first quarter. Dimensional Fund Advisors LP now owns 4,522,378 shares of the company's stock valued at $159,850,000 after acquiring an additional 109,595 shares during the period. Commodore Capital LP grew its stake in shares of Alkermes by 18.3% during the 1st quarter. Commodore Capital LP now owns 4,200,000 shares of the company's stock worth $148,512,000 after purchasing an additional 650,000 shares during the period. First Trust Advisors LP grew its stake in shares of Alkermes by 104.2% during the 1st quarter. First Trust Advisors LP now owns 2,968,785 shares of the company's stock worth $104,976,000 after purchasing an additional 1,514,783 shares during the period. Affinity Asset Advisors LLC grew its stake in shares of Alkermes by 35.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,350,000 shares of the company's stock worth $47,736,000 after purchasing an additional 350,000 shares during the period. Finally, Public Sector Pension Investment Board increased its holdings in shares of Alkermes by 59.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 1,082,205 shares of the company's stock valued at $43,158,000 after purchasing an additional 404,800 shares in the last quarter. Institutional investors and hedge funds own 95.21% of the company's stock.

Insider Buying and Selling at Alkermes

In other news, SVP Christian Nichols sold 7,576 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $49.23, for a total value of $372,966.48. Following the completion of the sale, the senior vice president directly owned 102,193 shares of the company's stock, valued at $5,030,961.39. This trade represents a 6.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the firm's stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the sale, the executive vice president directly owned 219,353 shares of the company's stock, valued at $10,127,528.01. This represents a 0.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 22,679 shares of company stock valued at $1,070,940. 4.59% of the stock is owned by corporate insiders.

Trending Headlines about Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: HC Wainwright raised its FY2027–FY2030 EPS forecasts, including moving FY2027 to $0.24 from a projected loss of $0.43 and FY2030 to $1.66 from $1.36. The improved outlook for later-year earnings may support investor optimism. Article: What Are Investment Firms Saying About This Stock?
• Neutral Sentiment: The firm kept its Neutral rating and $50 price target. It forecasts a return to positive annual EPS in 2027, while estimating a loss of $0.56 per share for 2026.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.28 per share from a loss of $0.23, a near-term earnings revision that could weigh on sentiment.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.